Stay updated on Pembrolizumab in SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in SCLC Clinical Trial page.
Latest updates to the Pembrolizumab in SCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2. This appears to be a minor version update with no impact on study content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe government funding lapse notice was removed from the page. The study content, endpoints, and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check52 days agoChange DetectedThe study record now displays Terminated status with the reason that standard of care for small cell lung cancer changed in 2018. Enrollment, primary completion, and study completion dates have been updated to reflect the termination.SummaryDifference0.4%
- Check73 days agoChange DetectedAdded government funding/status notice and new version v3.2.0; removed a specific resource entry (Small cell lung carcinoma) and older version v3.1.0.SummaryDifference3%
- Check80 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%
- Check95 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' link/button was removed.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab in SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in SCLC Clinical Trial page.